One company reshaped obesity treatment forever.
| Stat | Value |
|---|---|
| Avg body weight loss with Wegovy (STEP 1 trial) | 15% |
| Active GLP-1 products in Novo Nordisk's lineup | 5 |
| Monthly out-of-pocket cost without insurance | $900–$1,100 |
| Reduction in major cardiovascular events (LEADER trial) | 13% |
Key Takeaways
- Victoza (liraglutide): First-generation daily injection for type 2 diabetes with proven cardiovascular benefit from the LEADER trial.
- Ozempic (semaglutide 1mg): Weekly injection approved for T2D and cardiovascular risk reduction — the drug that launched the mainstream GLP-1 conversation.
- Wegovy (semaglutide 2.4mg): The obesity-specific formulation delivering 15% average weight loss; the same molecule as Ozempic at a higher dose.
- Rybelsus: Oral semaglutide (3–14mg) for T2D — first GLP-1 pill, taken daily on an empty stomach.
- Pipeline: CagriSema (semaglutide + cagrilintide) and amycretin targeting higher weight loss ceilings than Wegovy alone.
- Key limitation: Cost and supply constraints remain the biggest real-world barriers despite strong efficacy data.
Novo Nordisk didn't just develop a drug — they built a category. If you've heard anything about GLP-1 medications in the past three years, there's a good chance it centered on one of their products. Here's every GLP-1 drug they make, what each one actually does, and where the lineup is heading.
Why Novo Nordisk Owns the GLP-1 Space
It started with a molecule called semaglutide.
Most pharmaceutical companies develop drugs and move on. Novo Nordisk spent decades refining their GLP-1 molecule into multiple delivery formats — daily injections, weekly injections, and oral tablets — then took each to a separate FDA approval pathway. The result is a portfolio strategy that competitors are still scrambling to match. Their first-mover advantage in semaglutide, combined with manufacturing infrastructure built before demand exploded, gave them a lead that isn't shrinking fast.
Understanding their full lineup helps you understand what you're actually being prescribed — and why the dose and formulation you're on matters as much as the molecule itself.
Victoza (Liraglutide): The Original
Victoza came first, and it proved the concept.
Approved in 2010 for type 2 diabetes, liraglutide is a daily injectable GLP-1 agonist. It was the first drug in this class to demonstrate a cardiovascular benefit in a large outcomes trial. The LEADER trial — published in the New England Journal of Medicine in 2016 — showed a 13% reduction in major adverse cardiovascular events (MACE) in people with T2D and established cardiovascular disease. That single data point changed how cardiologists and endocrinologists thought about diabetes medication.
Victoza isn't a weight loss drug in its approved indication, but weight loss of around 3–4kg is common at therapeutic doses. In 2014, a higher-dose version of liraglutide (3mg) was approved specifically for obesity under the brand name Saxenda — technically a different product, but the same molecule, illustrating how Novo extracts multiple approvals from a single compound.
In 2026, Victoza is rarely a first-choice prescription. Semaglutide outperforms it on almost every metric. But liraglutide's cardiovascular data remains clean and well-replicated, and it still appears in certain combination regimens.
Ozempic (Semaglutide 1mg): The Cultural Moment
No drug in recent memory moved faster into public consciousness.
Ozempic was approved for type 2 diabetes in 2017 as a weekly injection. The semaglutide molecule is a modified version of the natural GLP-1 hormone, engineered to survive in the bloodstream for about a week — which is why you only inject it once instead of daily. The SUSTAIN trial program showed HbA1c reductions of roughly 1.5% from baseline, and the SUSTAIN-6 cardiovascular outcomes trial showed a 26% reduction in MACE risk.
Then came the weight loss data. Patients in trials weren't just improving their blood sugar — they were losing significant body weight. That observation eventually became Wegovy (see below), but not before Ozempic became a cultural phenomenon. Off-label use for weight loss drove massive demand that outpaced supply for over two years.
Ozempic is currently approved for T2D management and cardiovascular risk reduction in adults with T2D and known cardiovascular disease. It is not FDA-approved for obesity as a standalone indication — that's Wegovy's lane. The distinction matters for insurance coverage.
Wegovy (Semaglutide 2.4mg): The Weight Loss Benchmark
Same molecule. Higher dose. Different approval. Transformative results.
Wegovy is semaglutide at 2.4mg weekly — roughly 2.4 times the maximum approved dose in Ozempic. It was approved for chronic weight management in 2021 after the STEP trial program delivered data that genuinely surprised researchers. In STEP 1, participants without diabetes lost an average of 14.9% of body weight over 68 weeks, compared to 2.4% in the placebo group. That's not a rounding error — it's the kind of separation that gets drugs approved fast.
STEP 2 looked at people with type 2 diabetes, where weight loss averaged 9.6%. STEP 5 extended the trial to 104 weeks and showed the effect was durable — not a spike followed by return to baseline, but sustained weight loss as long as people stayed on the drug.
The SELECT trial, published in 2023, added another layer: Wegovy reduced major cardiovascular events by 20% in people with obesity and established cardiovascular disease but without diabetes. This was the first time an obesity drug had shown that kind of cardiovascular outcome data, and it changed how insurers and payers are thinking about covering these medications.
Wegovy requires gradual dose escalation over 16 weeks — starting at 0.25mg weekly and stepping up to 2.4mg — to manage gastrointestinal side effects like nausea, which affects a significant portion of users in the early weeks but typically improves.
Rybelsus (Oral Semaglutide): The Pill Version
A weekly injection isn't for everyone.
Rybelsus was approved in 2019 as the first oral GLP-1 agonist, available in 3mg, 7mg, and 14mg doses taken daily. Getting a peptide drug to survive digestion required a novel formulation with an absorption enhancer called SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate), which enables the semaglutide molecule to absorb through the stomach lining rather than being broken down.
The trade-off: Rybelsus must be taken on an empty stomach, at least 30 minutes before food or other medications, with no more than 4 ounces of water. That protocol creates a compliance challenge that injections don't have. Efficacy is also somewhat lower than injectable semaglutide — at 14mg, HbA1c reduction is comparable to low-dose Ozempic, but weight loss averages are lower.
Rybelsus is approved for type 2 diabetes only, not obesity. For patients who are needle-averse and managing T2D as the primary goal, it's a legitimate option. For people whose primary goal is significant weight loss, the data favors injectable formulations.
The Pipeline: What's Coming From Novo Nordisk
CagriSema is the most-watched drug in their pipeline.
CagriSema combines semaglutide with cagrilintide, an amylin analogue. Amylin is another gut hormone involved in appetite regulation, working through a different pathway than GLP-1. Early trial data showed weight loss of around 22–23% over 32 weeks in people with obesity — meaningfully higher than Wegovy alone. Phase 3 trials are underway, and Novo has positioned CagriSema as the next step up for patients who need more than semaglutide can deliver.
Amycretin is a single molecule that combines GLP-1 and amylin receptor activity. In a Phase 1 trial, it produced remarkable preliminary weight loss signals, though Phase 1 data is always early and the full picture takes years to develop. The concept is the same: activate multiple satiety pathways simultaneously to achieve weight loss that a single-mechanism drug can't reach.
The Real-World Limitations
The efficacy data is strong. The access picture is harder.
Wegovy and Ozempic both carry list prices in the $900–$1,100 per month range without insurance. Novo Nordisk offers savings programs, and coverage has expanded significantly since 2023 — but coverage varies widely by plan, employer, and state. Supply shortages disrupted access for a prolonged period after Wegovy launched; manufacturing has improved substantially but demand continues to grow faster than expected.
There's also the discontinuation question. The SELECT trial and STEP 5 data show that weight and blood sugar control returns toward baseline when people stop the medication. For most patients, these drugs are long-term commitments, not short-course treatments — and that changes the cost-benefit calculation meaningfully.
Neither of these limitations changes the underlying evidence. They're real-world friction points that determine who can actually access the drugs the trials described.
Which Novo Nordisk GLP-1 Drug Is Right for You?
That's a conversation for your prescriber — but the framework helps.
| Drug | Molecule | Delivery | Approved For | Avg Weight Loss |
|---|---|---|---|---|
| Victoza | Liraglutide | Daily injection | T2D | ~3–4 kg |
| Ozempic | Semaglutide 1mg | Weekly injection | T2D, CV risk | ~5–7 kg |
| Wegovy | Semaglutide 2.4mg | Weekly injection | Obesity, CV risk | ~15% body weight |
| Rybelsus | Oral semaglutide | Daily tablet | T2D | ~3–4 kg |
If weight loss is the primary goal, Wegovy is where the strongest evidence sits. If blood sugar management is the primary goal and injections aren't viable, Rybelsus is the oral option. Ozempic occupies the middle ground for people managing T2D who also see meaningful weight benefit.
Frequently Asked Questions
Is Ozempic the same as Wegovy?
They use the same molecule — semaglutide — but at different doses. Ozempic is approved at up to 1mg weekly for type 2 diabetes. Wegovy is approved at 2.4mg weekly specifically for chronic weight management. The higher dose produces greater weight loss but also a higher rate of gastrointestinal side effects during dose escalation.
Why was there a shortage of Novo Nordisk GLP-1 drugs?
Demand for Ozempic and Wegovy far exceeded supply projections after their cardiovascular outcome data was published and off-label prescribing expanded. Novo Nordisk has invested billions in manufacturing capacity, and supply has improved considerably since the peak shortage periods of 2022–2023.
What is CagriSema and when will it be available?
CagriSema combines semaglutide with cagrilintide, an amylin analogue. Phase 3 trials are underway as of 2025–2026. It is not yet FDA-approved. If Phase 3 data supports approval, the earliest realistic timeline would be 2026–2027, depending on regulatory review.
Does Novo Nordisk make a GLP-1 pill for weight loss?
Not yet with an obesity indication. Rybelsus (oral semaglutide) is approved only for type 2 diabetes. Novo Nordisk has been developing higher-dose oral semaglutide formulations (up to 50mg) specifically for obesity, with trials showing weight loss results approaching injectable performance. An FDA approval for that indication was expected in 2025–2026.
This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication or treatment.
